Program

S C I E N T I F I C      P R O G R A M

*All sessions will be in Potsdam I, unless specified otherwise

Friday, February 4, 2011

8:00

16:00 

Registration and Distribution of Materials

9:00 

10:30

SATELLITE SYMPOSIUM Sponsored by LEO Pharma

VTE and pregnancy: what we know, what we need to know

Chairs: Ian Greer, United Kingdom and Shannon Bates, Canada 

Welcome; Introduction to part 1

Ian Greer, UK and Shannon Bates, Canada

Clinical outcomes with the LMWH, tinzaparin in pregnancy: an international
retrospective study; Ian Greer, UK

Management of PE in pregnant patients; Florence Parent, France

ACCP guidelines for pregnancy: challenges and controversies; Shannon Bates, Canada

Coffee Break

Registry data from Norway on the role of risk factors in deciding whether prophylaxis is necessary after C-section; Anne Flem Jacobsen, Norway

Q & A session; Chairs and all speakers

Introduction to part 2 – interactive session; Chairs

Case 1: treatment; John Higgins, Ireland

Case 2: prophylaxis; Thomas Bergholt, Denmark

Summary; Chairs

12:30

Lunch sponsored by LEO Pharma

13:30

WHITH 2011 Opening Remarks    Benjamin Brenner, Israel and Ian Greer, UK

13:40-15:35

Session 1: CANCER AND THROMBOSIS IN WOMEN

Chairmen:       Anna Falanga, Italy

                          Dominique Farge-Bancel, France

13:40

Pathophysiology of Cancer and Thrombosis

Anna Falanga, Italy

14:05

Epidemiology of VTE in Women with Cancer

Manuel Monreal, Spain

14:30

Prevention of VTE in Women with Cancer

Alexander Cohen, UK

14:55

Treatment of VTE in Women with Cancer

Rupert M. Bauersachs, Germany

15:20

Selected Oral Abstracts

(1a) Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in
unselected Italian women; E. Grandone, D. Colaizzo, G. Tiscia, P. Vergura, F. Cappucci,
G.M. Maruotti, L. Greco, M. Margaglione, P. Martinelli, on behalf of PRENACEL study Group;
Italy

(1b) All trans-retinoic acid modulates the procoagulant activity of human breast cancer
cells; A. Falanga, L. Russo, D. Balducci, M. Marchetti; Italy

15:45-17:15

Session 2: PULMONARY EMBOLISM

Chairmen:       Guy Meyer, France

                          Catherine Nelson-Piercy, UK

Supported by an unrestricted educational grant from Sanofi-Aventis

15:45

Thromboprophylaxis after Cesarean Section: Decision Analysis

Marc Blondon, Switzerland

16:10

Diagnosis of Pulmonary Embolism in Pregnancy

Menno V. Huisman, the Netherlands

16:35

Pulmonary Hypertension in Pregnancy

Franco Piovella, Italy

17:00

Selected Oral Abstracts

(2a) Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of
venous thromboembolism; P.G. Lindqvist, K. Bremme, M. Hellgren; Sweden

(2b) Magnetic resonance imaging and ultrasonography in diagnosis of pelvic vein
thrombosis during pregnancy; A. Hagman, M. Torkzad, K. Bremme, M. Hellgren,
M.J. Eriksson, T. Jörgensen, K. Lund, G. Sandgren, L. Blomqvist, P. Kälebo; Sweden

17:15-18:30

POSTER SESSION & Coffee Break

20:00-22:00

Get Together Reception

Saturday, February 5, 2011

8:30-10:00

Session 3: BIOLOGIC BASIS OF HORMONAL EFFECTS ON
COAGULATION

Chairmen:       Per Morten Sandset, Norway

                         Jan Rosing, the Netherlands

8:30

Mice Models of Obesity and Hormonal Therapy

H. Roger Lijnen, Belgium

8:55

Thrombin Generation Tests

Elisabetta Castoldi, the Netherlands

9:20

Haemostasis and Hormonal Contraceptives: Different Agents, Different Effects 

Jacqueline Conard, France

9:45

Selected Oral Abstracts

(3a) A microarray study on the effect of four hormone therapy regimens on gene
transcription in leucocytes from healthy postmenopausal women; A.E.A. Dahm,
A.L. Eilertsen, J. Goeman, O.K. Olstad, R. Ovestebo, P. Kierulf, M.-C. Mowinchel,
G. Skretting, P.M. Sandset; Norway, the Netherlands

(3b) SNPS in the SULT1E1 gene and the risk of oral contraceptive-associated venous
thrombosis; B.H. Stegeman, H.L. Vos, F.M. Helmerhorst, A. van Hylckama Vlieg,
P.H. Reitsma, F.R. Rosendaal; the Netherlands

10:00-10:30

Coffee Break & Exhibition Visit

10:30-12:00

Session 4: HORMONAL THERAPY AND THROMBOSIS

Chairmen:       Paolo Simioni, Italy

                        Emmanouil Papadakis, Greece   

10:30

Epidemiology of Hormonal Replacement Therapy and Thrombosis

Pierre-Yves Scarabin, France

10:55

Epidemiology of OCP and Thrombosis

Phillip Hannaford, UK

11:20

Controversies in Postpartum Contraception: When Is It Safe to Start OCP after
Childbirth

Emily Jackson, Switzerland

11:45

Selected Oral Abstracts

(4a) Risk of VTE during combined oral contraceptive use and pregnancy in women with
mild thrombophilia; E.F.W. van Vlijmen, N.J.G.M. Veeger, S. Middeldorp, K. Hamulyák,
M.H. Prins, H.R. Büller, K. Meijer; the Netherlands

(4b) Effect of the dose of oral treatment with 17beta-estradiol associated with
dydrogesterone on thrombin generation in healthy postmenopausal women: a
randomized double-blind placebo-controlled study; G. Gerotziafas, V. Galea,
A. Rousseau, D. Torchin, K.F. Zannad, K. Lacut, J. Demolis, T. Simon, I. Elalamy; France

12:00

SATELLITE LUNCH SYMPOSIUM Sponsored by Sanofi-Aventis

Novel Mechanisms - New Interventions

Chairmen:  Ian A Greer, UK and Benjamin Brenner, Israel

Extended prophylaxis in medical patients

S.M. Schellong, Germany

Heparanase involvement in the placenta

Yona Nadir, Israel

Pregnancy complications as a risk factor to future vascular disease

Ian A Greer, UK

New anticoagulants: potential role in pregnancy?

Ida Martinelli, Italy

Anticoagulants for prevention of miscarriages and gestational vascular complications:
which trials in which patients?

    Moderator:  Benjamin Brenner

    Discussants: Marc Rodger, Jean-Christophe Gris, Saskia Middeldorp, Risto Kaaja

14:00-15:55

Session 5: ANTIPHOSPHOLIPID SYNDROME

Chairmen:       Jacob H. Rand, USA

                         Beatriz E. Grand, Argentina

Biologic Basis of Disease in APS

14:00

a. Mechanisms of APLA Formation

Philip de Groot, the Netherlands  

14:25

b. Role of Complement in Gestational Complications

Guillermina Girardi, USA

APS – Controversies in Diagnosis and Management

14:50

a. Unusual Clinical Presentations

Mike Greaves, UK 

15:15

b. Critical Overview of Current Guidelines

Vittorio Pengo, Italy

15:40

Selected Oral Abstracts

(5a) Antiphospholipid antibodies and the risk of intrauterine fetal death – Results of a
case–control study; L.B. Helgadóttir, F.E. Skjeldestad, A.F. Jacobsen, P.M. Sandset,
E.M. Jacobsen; Norway

(5b) Low molecular weight heparin actions on human endometrial angiogenesis;
N. Di Simone, C. Tersigni, F. Di Nicuolo, S. D’Ippolito, R. Castellani, R. Marana, J. Stinson;
Italy, Denmark

16:00-16:30

Coffee Break & Exhibition Visit

16:30-18:00

Session 6: ARTERIAL THROMBOSIS

Chairmen:       Andra H. James, USA

            Silvia Hoirisch Clapauch, Brazil

16:30

Vascular Complications in Diabetic Pregnancy

Risto Kaaja, Finland

16:55

Mechanical Heart Valves  - Anticoagulation in Pregnancy

Claire McLintock, New Zealand

17:20

Resistance to Anti-Platelet Agents

Marco Cattaneo, Italy

17:45

Selected Oral Abstracts

(6a) Nocturnal variability of coagulation in gestational diabetes; M. Pöyhönen-Alho,
R. Kaaja; Finland

(6b) Role of protein S and tissue factor pathway inhibitor in the development of APC
resistance early in pregnancy; S.N. Tchaikovski, M.C.L.G.D. Thomassen, S.D. Costa,
L.L.H. Peeters, J. Rosing; The Netherlands, Germany

(6c) Oligoamenorrhea, high weight accrual rate, acanthosis and first trimester hypertriglyceridemia are independent predictors of preeclampsia; S. Hoirisch Clapauch,
P.R. Benchimol-Barbosa; Brazil

20:00

Farewell Dinner (Optional)

Sunday, February 6, 2011

8:30-10:30

Session 7: GESTATIONAL VASCULAR COMPLICATIONS

Chairmen:       Simcha Yagel, Israel

                          Gus Dekker, Australia

8:30

Angiogenesis in Gestational Vascular Complications

Simcha Yagel, Israel

8:55

Microparticles and Pregnancy Complications

Anat Aharon, Israel

9:20

New insights into the aetiology of preeclampsia: identification of key elusive factors
for the vascular complications.

Asif Ahmed, UK

9:45

LMWH for Prevention of Placental Insufficiency

Marc Rodger, Canada

10:10

Selected Oral Abstracts

(7a) Enoxaparin for the secondary prevention of placental vascular complications in
women with severe pre-eclampsia: the pilot randomised controlled NOH-PE study;
J.C. Gris, C. Chauleur, P. Marès, I. Quéré , J.Y. Lefrant, B. Haddad, M. Dauzat; France

(7b) Low molecular weight heparin versus no treatment in women with previous
severe pregnancy complications and placental findings without thrombophilia;
M. Kupferminc, E. Rimon, A. Many, S. Maslovitz, J.B. Lessing, R. Gamzu; Israel

10:30-11:00

Coffee Break & Exhibition Visit

A.11:00-12:30

(Potsdam I)

Session 8: UNEXPLORED VENOUS THROMBOSIS IN WOMEN

Chairmen:       Ida Martinelli, Italy    

            Rainer B. Zotz, Germany

11:00

Superficial Thrombophlebitis

Herve Decousus, France

11:25

Venous Thrombosis at Unusual Sites

Walter Ageno, Italy

11:50

Postphlebitic Syndrome

Susan R. Kahn, Canada

12:15

Selected Oral Abstracts

(8a) Prevalence and predictors for post-thrombotic syndrome (PTS) three to 16 years
after first-time pregnancy related venous thrombosis – a population-based case–
control study; H.S. Wik, A.F. Jacobsen, L. Sandvik, P.M. Sandset; Norway

(8b) Reduced sensitivity to activated protein C in the absence of the factor V Leiden polymorphism is a risk factor for pregnancy related venous thrombosis; A. Bergrem,
A.E.A. Dahm, A.F. Jacobsen, M.C. Mowinckel, L. Sandvik, P.M. Sandset; Norway

B. 11:00-12:30

(Potsdam III)

Session 9: PLACENTAL HEMOSTASIS

Chairmen:       Berend H. Isermann, Germany

            Michael Kupferminc, Israel

11:00

Tissue Factor Expression on Decidual Cells

Charles J. Lockwood, USA

11:25

Is Placental Haemostasis Relevant to Recurrent IVF Failure?

Scott Nelson, UK

11:50

Placental Pathology in Pregnancy Complications

Berthold Huppertz, Austria

12:15

Selected Oral Abstracts

(9a) Microparticles’ effect on apoptosis, angiogenesis and migration in healthy and
pathological pregnancies; E. Shomer, S. Katzenell, Y. Zipori, R.N. Sammour, B. Brenner,
A. Aharon; Israel

(9b) p45NF-E2 epigenetically represses Gcm1 in trophoblast cells, regulating
syncytium formation, placental vascularization and embryonic growth; M. Kashif,
A. Helwig, M. Thati, K. Shahzad, H. Wang, T. He, S. Ranjan, J. Wolter, P.P. Nawroth,
B. Isermann; Germany

12:30-13:15

Lunch

13:15-15:00

Session 10: HEPARINS IN PREGNANCY

Chairmen:       Peter Clark, UK

                          Pelle Lindqvist, Sweden

Supported by an unrestricted educational grant from Sanofi-Aventis

13:15

Biosimilar Heparin Derivatives

Job Harenberg, Germany

13:40

Monitoring of LMWH in Pregnancy: When and How

Carl-Erik Dempfle, Germany

LMWH Have No Place  In Recurrent Pregnancy Loss:  Debate

14:05

• · Saskia Middeldorp, the Netherlands – For the motion

14:25

• · Jean-Christophe Gris, France – Against the motion

14:45

Selected Oral Abstracts

(10a) Risk of PPH in women using therapeutic dosage of LMWH during pregnancy
and puerperium; H.M. Knol, L. Schultinge, J.J.H.M. Erwich, N.J.G.M. Veeger,
H.C. Kluin-Nelemans, K. Meijer; the Netherlands

(10b) Low-molecular-weight heparin for prevention of obstetric complications in
carriers of factor V Leiden or PT-G20210A mutation; D. Tormene, E. Grandone,
V. De Stefano, G. Palareti, G. Castaman, M. Margaglione, A. Ciminello, L. Valdrè,
A. Tosetto, P. Simioni; Italy

15:00 -16:30

Session 11: BLEEDING IN WOMEN AND NEONATES

Chairmen:       Rezan Abdul-Kadir, UK

            Ulrike Nowak-Göttl, Germany 

15:00

Antifibrinolytic Agents for Menorrhagia

Claire S. Philipp, USA

15:25

Post-Partum Hemorrhage in Women with Bleeding Disorders

Flora Peyvandi, Italy

15:50

Neonatal IVH - Mechanisms and Management

Gili Kenet, Israel

16:15

Selected Oral Abstracts

(11a) Tranexamic acid reduces blood loss in post-partum haemorrhage;
A.S. Ducloy-Bouthors, A. Duhamell, S. Susenl, F. Broisin, C. Huissoud, H. Keita-meyer,
L. Mandelbrot, N. Tillouche, S. Fontaine, F. le Goueff, S. Depret-Mosser, B. Jude,
the EXADELI centres and Investigators; France

(11b) Gynaecological and obstetric bleeding in moderate and severe Von Willebrand
Disease; E.M. de Wee, H.M. Knol, E.P. Mauser-Bunschoten, J.G. van der Bom,
M.E.L. Degenaar-Dujardin, J.C.J. Eikenboom, K. Fijnvandraat, A. de Goede-Bolder,
B. Laros-van Gorkom, P.F. Ypma, S. Zweegman, K. Meijer, F.W.G. Leebeek, for the WiN
study group; the Netherlands

16:30

Concluding Remarks - Symposium Chairmen

Meeting Adjourned